Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

AZD 4573

Next Previous
Search
Drug Profile

AZD 4573

Alternative Names: AZD-4573

Latest Information Update: 27 Apr 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator AstraZeneca Pharmaceuticals
  • Class Amides; Antineoplastics; Cyclohexanes; Pyrazoles; Pyridines; Small molecules
  • Mechanism of Action Cyclin-dependent kinase 9 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Haematological malignancies

Most Recent Events

  • 27 Feb 2025 AstraZeneca completes a phase I/II trial in Haematological malignancies (Combination therapy, In the elderly, Late-stage disease, Second-line therapy or greater, In adults) in United Kingdom, Spain, Poland, South Korea, Ireland, France, Canada, Australia (IV) as of November 2022 (NCT04630756)
  • 07 Dec 2024 Pharmacodynamics data from a preclinical trial in T-cell lymphoma presented at the 66th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2024)
  • 07 Apr 2024 Pharmacodynamic data from a preclinical study in Colorectal cancer presented at the 115th Annual Meeting of the American Association for Cancer Research (AACR-2024)

You need to be a logged in or subscribed to view this content Request demo (opens in a new window)

If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top